Introduction
Non-small-cell lung cancer (NSCLC), when untreated, proves invariably deadly in the vast majority of patients within 1 year. 1 NSCLC is diagnosed at advanced stages (III or IV) in 70% of the cases in the USA, and 19%-24% of the individuals with advanced NSCLC are never treated. 2, 3 Furthermore, untreated NSCLC accounts for 55% of all untreated advanced cancers in the USA. 3 There are multiple reasons why patients do not receive therapy; however, comorbidity consistently stands out as a reported predictor for lack of therapy for NSCLC patients. [4] [5] [6] Comorbidity burden has been described to be higher along with the high prevalence of smoking in lung cancer compared with other types of solid tumors. 7 The presence of comorbidities can influence treatment selection due to organ damage or increased risk of adverse effects. Currently, it remains unclear if the comorbidity burden alone is predictive of outcome in a lung cancer patient or only when it affects patient's performance status. 5 Similarly, there are limited data regarding the actual benefit of treating lung cancer in patients with a high comorbidity burden. In this study, we aim to evaluate the association of comorbidities with the treatment and the survival of NSCLC patient population along with the degree of benefit from treatment in those patients with comorbidities.
Methods

Patient population and eligibility criteria
A retrospective cohort study of patients aged ≥66 years diagnosed with invasive NSCLC stages I through IV between the years 2007 and 2011 in the state of Kentucky, was performed using data from the Surveillance, Epidemiology, and End Results (SEER) registry linked to claim files from the US Medicare database (SEER-Medicare). Medicare provides insurance to elderly Americans and this study included patients who had continuous Medicare part A (hospital insurance) and part B (medical insurance) coverage 12 months prior and 6 months after lung cancer diagnosis or death, whichever came first. We excluded patients with health maintenance organization coverage in the previous 12 months, those with Medicare eligibility due to end-stage renal disease or disability, and those with a concurrent diagnosis of cancer within 3 months of lung cancer diagnosis (Figure 1 ). The chair granted an Institutional Review Board approval after an expedited review application at the University of Louisville, Kentucky.
Cancer treatment
Treatment information was obtained from both registry and claims data. Surgical treatment data were obtained using the SEER Kentucky Cancer Registry (KCR) surgery codes and claims data from the SEER Medicare Provider Analysis and Review (MEDPAR) and Carrier Claims -National Claims History (NCH) files. Radiation treatment and chemotherapy data were obtained using KCR treatment codes, MEDPAR, NCH, and the SEER outpatient claim files. Furthermore, the SEER Durable Medical Equipment and Prescription Drug Event files were evaluated to determine the use of chemotherapy. A full description of the specific codes used can be found in Tables S1 and S2 .
Variables of interest
Age at the time of diagnosis, race/ethnic information and the stage at diagnosis were obtained from KCR. Race/ ethnicity was categorized into 3 groups: White, black, and other. Comorbidity burden on diagnosis was measured using the lung cancer-specific Klabunde Comorbidity Index (KCI). 8 The KCI, a continuous comorbidity index based on the comorbid conditions identified by Charlson index that incorporates the diagnostic and procedure data from physician claims, was converted into a categorical variable of increasing severity of comorbidity: no and very low comorbidity (KCI=0), low comorbidity (KCI=1), moderate comorbidity (KCI=2), and high comorbidity (KCI≥3). 8 Poverty at the residential census tract level was categorized in 4 groups according to the percentage of residents with an income below the US federal poverty line (<8%, 8%-15%, 15%-30%, or >30%). Education at the residential census tract level was categorized into 4 groups based on the proportion of adult residents (≥25 years old) with less than high school education (<15%, 15%-25%, 35%-35%, and >35%). Geographic origin of the patient was classified into metropolitan versus rural origin and Appalachian versus 
Statistical analysis
Descriptive analysis and χ² tests were used to assess the association between treatment status and covariates. Multivariate logistic regression models were used to explore the association between receiving treatment and comorbidity, while accounting for the potential confounding effect of other covariates. The interaction effects and the goodness of fit were examined. The final model only included the significant covariates. Kaplan-Meier estimates and log-rank tests were calculated to examine the survival curves of various treatment and comorbidity combinations. Cox regression survival models were fitted to identify the significant factors associated with survival while controlling for other covariates. All tests were 2-sided with a 0.05 significance level. SAS 9.3 was used for all analysis.
Results
We identified 4014 cases of invasive NSCLC as eligible for analysis. Most patients (94.9%) were Caucasian, and 55.7% were male. Approximately half of the patients lived in rural areas (48%). KCI scores were 0 (no or very low comorbidity), 1 (low comorbidity), 2 (moderate comorbidity), and ≥3 (severe comorbidity) in 46.8%, 29.1%, 10.8%, and 13.3% of the study sample, respectively.
Receiving lung cancer treatment
The proportion of patients by stage who did not receive any treatment for lung cancer were 8.7%, 3.9%, and 19.1% for stage I, stage II, and stage III, respectively (p<0.0001). A total of 49.1% of stage IV patients did not receive any chemotherapy and 23.5% of this cohort did not receive any treatment modality (p<0.0001). Compared with the treated individuals, the untreated population had a higher proportion of patients >75 years old, diagnosed at stage IV, residing in rural areas, having higher comorbidity index scores, and more likely to live in areas of lower education levels. Of the patients with a KCI≥3%, 25.4% were untreated, compared with 16.4% of patients with KCI=0%, 15.7% with KCI=1%, and 18.2% with KCI=2 (p<0.0001) ( Table 1) . Across all stages, the proportion of patients with high comorbidity (KCI ≥3) was similarly distributed (15.2% in stages I-II, 12.9% in stage III, and 12% in stage IV). In multivariate analysis, older age, more advanced stage, higher comorbidity index, and residency in rural areas were significantly associated with a lower likelihood of receiving lung cancer treatment.
Survival analysis
In patients with KCI=0, the median OS for the untreated group was 17.7 months for stages I and II, 2.3 months for stage III, and 1.3 months for stage IV. For KCI=0 patients who received treatment, the median OS was 58.9, 16.8, and 5.8 months for stages I and II, III, and IV, respectively ( Figures 2-4 ). In patients with KCI ≥3, the median OS for the untreated group was 6.1, 1.6, and 1.2 months for stages I and II, III, and IV, respectively. For the KCI ≥3 patients who received any treatment, the median OS was 22.9, 10.9, and 3.7 months for stages I and II, III, and IV, respectively (Figures 2-4) . In multivariate Cox regression models, age, gender, stage, KCI scores, and receiving treatment were associated with survival (Table 2 ). In particular, higher comorbidity was independently associated with lower OS (HR=1.51 for KCI≥3 vs KCI=0; 95% CI 1.363-1.679; p<0.001).
Within each comorbidity index level, patients who received no therapy had worse survival than those who received any therapy (Table 3 ).
Discussion
Our study confirms the previously reported association between the presence of comorbidities and lower likelihood of receiving cancer treatment. [4] [5] [6] However, conflicting data were found with regard to the association between comorbidities and on survival of lung cancer patients. Luchtenborg et al 9 found that severe comorbidity had a large detrimental impact on the survival of lung cancer patients who undergo curative lung resection. In contrast, a retrospective cohort study from the Netherlands showed that the negative effect of comorbidity on survival in nonsurgical candidates was present only in patients treated with chemotherapy. 10 In an analysis of all cancer cases diagnosed between 1992 and 2005 included in the US SEER database, Edwards et al 7 found that the influence of comorbidities on the probability of both cancer-specific and non-cancer-related mortality was smaller for lung cancer compared with other cancers. Our study adds to the body of evidence suggesting that comorbidities influence physicians' decision to recommend treatment for NSCLC, and that comorbidity levels may correlate with Despite the role of comorbidity assessments in the choice of treatments, limited data are available about the actual benefit of lung cancer therapy in patients with high comorbidity burden. Patients who are more sick are more likely to be excluded from standard clinical trials, leaving clinicians with little objective assessments of treatment benefits in the setting of high comorbidities. Furthermore, when considering the toxicity profile of chemotherapy, the intensity of treatment is limited by organ function, which can be directly impacted by the presence of comorbidities. Patients with higher burden of comorbidities, as determined by KCI score of 3 or higher, constituted ~15% of our study population. In this group, we 
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Treatment and outcomes for NSCLC patients observed significantly higher survival among those individuals who received any cancer-specific therapy compared with their equally comorbid counterparts who did not. Although selection bias could have resulted in overestimated measures of treatment effects in this observational study, our data indicate that patients may still derive a survival benefit from cancer treatments in the presence of high comorbidity. Likewise, we recognize that comorbidity is not a sole factor used to decide against treatment in NSCLC patients. Not all comorbid conditions are expected to have an equal impact on the treatment. The most common comorbidities in lung cancer patients are chronic obstructive pulmonary 
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Rios et al disease, coronary artery disease, congestive heart failure, diabetes, and renal insufficiency. [4] [5] [6] Cardiac comorbidity and chronic obstructive pulmonary disease have been described as independent risk factors affecting the development of toxicity and the effectiveness of cancer therapy. [11] [12] [13] In contrast, no clear role has been described for other comorbidities (such as liver disease or Alzheimer's dementia) that are also included in the construction of the KCI. Moving forward, it is important for health care providers and patients to realize that, with newer therapeutic options such as immunotherapy, organ dysfunction and the comorbidity burden should play a lesser role in the decision to treat lung cancer.
There are several limitations to our analysis. The data set is from 2007 to 2011 and may not reflect more current practice patterns. This is particularly important since the recent development of immunotherapy, which is believed to have a more favorable safety profile and might not be affected by comorbidities compared with the safety profile of cytotoxic chemotherapy. Given that the study population is restricted to Kentucky residents, the results may not be generalizable to the US NSCLC population. [14] [15] [16] [17] [18] [19] The SEER-Medicare database does not provide data on other clinically relevant prognostic 
Conclusion
NSCLC patients with higher comorbidity burden are less likely to receive cancer-specific treatment and more likely to die.
However, it appears that even in individuals with high comorbidity burden, cancer-specific treatments seem to improve survival, independently of their stage at presentation. The treatment benefit observed in the high comorbid population is likely a result of multiple factors, including the treatment itself. The impact of comorbidity along with performance status, medical and social support system, and the presenting stage play an important role in decision to treat lung cancer. 
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